

Repositioning Drugs for Psychiatry

Drug development can be time-consuming and expensive. Recent estimates suggest that, on average, it takes 10 years and at least \$1 billion to bring a drug to market. Since last decade, 30-40% of drugs or biologics that were approved or launched for the first time in the US were either drugs repositioned for new indications, reformulations or new combinations of existing drugs. This is the lifecycle business with repositioning as a major contributor, and it is rarely given much attention outside of its practitioners^{1,2}.

In general, drug repurposing or drug repositioning alludes to the development of existing drugs or pro-drugs for new indications, not necessarily related to the original disease focus. These drugs have probably failed in late-stage clinical trials by lacking in efficacy or safety, or have problems associated with commercial strategies, patent expiration or geographic expansion. Repositioning existing drug substances for the treatment of different indications can significantly reduce the cost and time required for the development of new medicines. Therefore, drug repurposing brings forth the benefit of quickening patient access to innovative and effective treatment at lower risk and development cost for the industry^{1,2}.

There are a number of different definitions of drug repurposing. All of them contain two key elements:

Taking existing scientific or medical knowledge and technology that is "approved" for human use in one disease or condition; and

Applying this knowledge and technology to another disease or condition.

Aspirin, a drug that's been in use in some form or other for many hundreds of years was originally employed, and indeed still is, as a mild pain-relieving analgesic. But it's probably more commonly used today as an antiplatelet agent helping to prevent blood clotting that can occur in thromboembolic disease.

Nervous system diseases represent a major health concern worldwide. Although important financial and professional investment, their etiology and pathophysiology still remain mostly elusive. Moreover, the clinical need of disease-modifying therapies is still unmet. In medicine in general and in psychiatry in particular, repositioning was the result of serendipitous but astute clinical observation of an unexpected benefit or expected or unexpected adverse effects³. A number of old drugs have been reintroduced for psychiatric indications such as celecoxib for schizophrenia, tamoxifen for mania and scopolamine for depression⁴⁻⁷. Drug repurposing has become a new business segment for the life science services industry. In conclusion, drug repurposing emerges as a new value proposition for the industry, patients and payers.

References

1. Langedijk J, Mantel-Teeuwisse AK, Slijkerman DS, Schutjens MH. Drug repositioning and repurposing: terminology and definitions in literature. *Drug Discov Today* 2015;20(8):1027-1034.
2. Tiriveedhi V. Impact of precision medicine on drug repositioning and pricing: A too small to thrive crisis. *J Pers Med* 2018;8(4):36.
3. Hong J, Bang M. Anti-inflammatory strategies for schizophrenia: A review of evidence for therapeutic applications and drug repurposing. *Clin Psychopharmacol Neurosci* 2020;18(1):10-24.
4. Akhondzadeh S. The 5-HT hypothesis of schizophrenia. *IDrugs* 2001;4(3):295-300.
5. Abbasi SH, Behpournia H, Ghoreishi A, Salehi B, Raznahan M, Rezazadeh SA, et al. The effect of mirtazapine add on therapy to risperidone in the treatment of schizophrenia: a double-blind randomized placebo-controlled trial. *Schizophr Res* 2010;116(2-3):101-106.
6. Khajavi D, Farokhnia M, Modabbernia A, Ashrafi M, Abbasi SH, Tabrizi M, et al. Oral scopolamine augmentation in moderate to severe major depressive disorder: a randomized, double-blind, placebo-controlled study. *J Clin Psychiatry* 2012;73(11):1428-1433.
7. Abbasi SH, Hosseini F, Modabbernia A, Ashrafi M, Akhondzadeh S. Effect of celecoxib add-on treatment on symptoms and serum IL-6 concentrations in patients with major depressive disorder: randomized double-blind placebo-controlled study. *J Affect Disord* 2012;141(2-3):308-314.

*Shahin Akhondzadeh Ph.D., FBPhS.
Psychiatric Research Center, Roozbeh Hospital,
Tehran University of Medical Sciences, Tehran, Iran*